Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Glofitamab With Alternating R-CHOP/R-DHAP in Previously Untreated Mantle Cell Lymphoma

NCT07444710 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT07444710
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07444710 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Glofitamab With Alternating R-CHOP/R-DHAP in Previously Untreated Mantle Cell Lymphoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 30, 2026
Completion date
September 1, 2027
Enrollment
16 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ann arbor stage ii mantle cell lymphoma, ann arbor stage iii mantle cell lymphoma, ann arbor stage iv mantle cell lymphoma